Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 24, 2010Journal of Clinical OncologyOpen Access

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

KNKim N.BC Cancer AgencySHSebastién J. HotteJuravinski Cancer CentreEYEvan Y. YuUniversity of Washington

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

N. et al. (2010) studied this question.

synapsesocial.com/papers/6a71c0b326a7f98052ddf4c3https://doi.org/10.1200/jco.2009.26.8771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer2008 · 119 citations
  2. 2Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer2003 · 679 citations
  3. 3Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group1999 · 985 citations
  4. 4Knock‐down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers2005 · 42 citations
  5. 5Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 99162009 · 217 citations